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Introduction {#jdi12625-sec-0005}
============

It is well known that type 2 diabetes is characterized by β‐cell dysfunction and insulin resistance. In type 2 diabetes management, addressing obesity is considered to be an important factor, which might help to improve both the insulin resistance and the glycemic control[1](#jdi12625-bib-0001){ref-type="ref"}, [2](#jdi12625-bib-0002){ref-type="ref"}; therefore, weight loss is recommended for patients with type 2 diabetes[3](#jdi12625-bib-0003){ref-type="ref"}. It was suggested that approximately 5--10% of weight loss might improve glycemic control[4](#jdi12625-bib-0004){ref-type="ref"}, and other cardiovascular risk factors and comorbidities[5](#jdi12625-bib-0005){ref-type="ref"}, [6](#jdi12625-bib-0006){ref-type="ref"}. However, although there are a number of antidiabetes agents currently available, we should confess that it is still very difficult for type 2 diabetes patients to achieve optimal weight reduction as well as glycemic control. It is suggested that metformin provides modest weight reduction, whereas sulfonylureas and thiazolidinediones lead to weight gain, and dipeptidyl peptidase‐4 inhibitors are associated with weight neutral[1](#jdi12625-bib-0001){ref-type="ref"}, [7](#jdi12625-bib-0007){ref-type="ref"}.

Recently, it was reported in some clinical trials that glucagon‐like peptide‐1 (GLP‐1) analogs had a unique efficacy in weight reduction for both obesity and type 2 diabetes[8](#jdi12625-bib-0008){ref-type="ref"}, [9](#jdi12625-bib-0009){ref-type="ref"}, [10](#jdi12625-bib-0010){ref-type="ref"}. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors, have a mechanism of causing urinary glucose excretion through inhibiting renal glucose reabsorption by SGLT2, also providing both glycemic control and bodyweight reduction[11](#jdi12625-bib-0011){ref-type="ref"}, [12](#jdi12625-bib-0012){ref-type="ref"}, [13](#jdi12625-bib-0013){ref-type="ref"}, [14](#jdi12625-bib-0014){ref-type="ref"}. Both of the aforementioned kinds of antidiabetes agents might lead to bodyweight reductions different from other antidiabetes agents. However, which of the two kinds of agents is superior? So far, a head‐to‐head comparative study of these two kinds of antidiabetes agents has not been carried, out and no results could be found about weight changes. Therefore, to evaluate the efficacy of weight changes of GLP‐1 analogs and SGLT2 inhibitors, we carried out the present meta‐analysis.

Methods {#jdi12625-sec-0006}
=======

Search strategy {#jdi12625-sec-0007}
---------------

We mainly searched data from MEDLINE^®^ (PubMed), from 2004 until June 2015, and re‐searched in July 2016. The following terms were used: dapagliflozin; canagliflozin; empagliflozin; ipragliflozin; tofogliflozin; sodium glucose co‐transporter 2 inhibitors; exenatide; liraglutide; albiglutide; taspoglutide; lixisenatide; glucagon‐like peptide‐1 analogs; type 2 diabetes; randomized controlled trials. Furthermore, documents for medications (dapagliflozin, canagliflozin, empagliflozin, ipragliflozin, liraglutide, exenatide, albiglutide, taspoglutide, lixisenatide) were searched for trials at the clinical trials website.

Data selection and data extraction {#jdi12625-sec-0008}
----------------------------------

Studies meeting the inclusion criteria were included in this meta‐analysis: (i) randomized trial of SGLT2 inhibitors treatment compared with placebo in type 2 diabetes participants as monotherapy or add‐on therapy; (ii) randomized trial of GLP‐1 analogs treatment compared with placebo in type 2 diabetes participants as monotherapy or add‐on therapy; (iii) study length should be more than 12 weeks; (iv) change in the weight from baseline was provided in both the antidiabetes agent group and the placebo group; and (v) baseline characteristics, such as as age, body mass index (BMI) or glycated hemoglobin (HbA1c), were reported in the trial. Monotherapy was defined as patients not receiving any hypoglycemic agent before being randomized into the clinical trials, and after randomization, they received active hypoglycemic agent or a placebo. Add‐on therapy was defined as patients receiving hypoglycemic agents before randomization, but not well controlled, then after randomization, they received another active hypoglycemic agent or placebo add‐on to their previous treatment as the protocol defined.

Based on the inclusion criteria, WY and YC evaluated the eligibility of the studies independently. When disagreements between the two authors arose, they consulted with another investigator (LZ). By using the Cochrane instrument, we evaluated the quality of each study. Details are shown in supplement figures.

By using a standard form, WY and YC independently carried out the data extraction. Study titles and authors, study design, the number of individuals, patients\' age, diabetes duration, baseline HbA1c, dosage of the study drugs, duration of follow up, and the changes of bodyweight were all documented. If there was any disagreement, the two review authors (WY and YC) would discuss together with another investigator (LZ).

Statistical analysis {#jdi12625-sec-0009}
--------------------

We used weighted mean difference (WMD) and 95% confidence intervals (CIs) to evaluate the placebo‐corrected weight changes in the treatment of SGLT2 inhibitors and GLP‐1 analogs separately. The statistical analysis has been reported previously[15](#jdi12625-bib-0015){ref-type="ref"}. Meta‐regression was carried out to find the association between the bodyweight changes and the baseline age, sex, duration of diabetes, baseline BMI or baseline HbA1c (*P* \< 0.05 shows significance). The meta‐analyses were carried out by the Review Manager statistical software package (version 5.2; The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark), and the meta‐regression analyses were carried out by the Stata statistical software package (version 11.0; StataCorp, College Station, Texas, USA).

Results {#jdi12625-sec-0010}
=======

Characteristics of included studies {#jdi12625-sec-0011}
-----------------------------------

The flowchart of the study selection process is shown in Figure [1](#jdi12625-fig-0001){ref-type="fig"}. In total, 97 studies were relevant, including 51 studies with SGLT2 inhibitors (SGLT2i) treatment (17 studies as monotherapy and 34 studies as add‐on therapy) and 46 studies with GLP‐1 analogs (GLP‐1) treatment (15 studies as monotherapy and 31 studies as add‐on therapy). A reference list and clinical characteristics of studies are presented as Table [S1](#jdi12625-sup-0001){ref-type="supplementary-material"}. Characteristics of the individuals receiving SGLT2i and GLP‐1 analogs treatment in this meta‐analysis are shown in Table [1](#jdi12625-tbl-0001){ref-type="table-wrap"}. This meta‐analysis was based on data from 8,710 individuals in the SGLT2i treatment, and 7,409 individuals in the GLP‐1 analogs treatment.

![The flowchart of included studies. GLP‐1, glucagon‐like peptide‐1; HBA1c, glycated hemoglobin; SGLT2, sodium‐glucose cotransporter 2.](JDI-8-510-g001){#jdi12625-fig-0001}

###### 

Baseline characteristics of studies included in this meta‐analysis in sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment

                           SGLT2 inhibitors   GLP‐1 analogs
  ------------------------ ------------------ ---------------
  No. studies              51                 46
  Age (years)              57.1 ± 4.3         55.5 ± 2.2
  Male (%)                 44                 47
  Baseline BMI (kg/m^2^)   30.4 ± 2.7         31.1 ± 4.6
  Baseline weight (kg)     84.7 ± 8.3         88.4 ± 12.3
  DM duration (year)       7.5 ± 4.4          6.4 ± 2.8
  Baseline HbA1c (%)       8.1 ± 0.4          8.0 ± 0.4
  Study duration (weeks)   30.2 ± 22.0        26.4 ± 22.4

BMI, body mass index; DM, diabetes mellitus; GLP‐1, glucagon‐like peptide‐1; HBA1c, glycated hemoglobin; SGLT2, sodium‐glucose cotransporter 2.

John Wiley & Sons, Ltd

Quality of methodology {#jdi12625-sec-0012}
----------------------

The present meta‐analysis included studies that were randomized, placebo‐controlled and with double‐blind treatment. Most studies reported baseline age, sex, BMI, HbA1c and diabetes duration between the comparison groups. The visual inspection of the funnel plots showed an even distribution of the variables that were studied (Figures [S5](#jdi12625-sup-0002){ref-type="supplementary-material"}, [S6](#jdi12625-sup-0002){ref-type="supplementary-material"}). For the low level of heterogeneity, the fixed‐effects model was used, and for the high level of heterogeneity, the random‐effects model was used.

Weight changes in SGLT2 inhibitors treatment {#jdi12625-sec-0013}
--------------------------------------------

When SGLT2 inhibitors treatment was compared with placebo treatment, analysis of the combined data suggested that SGLT2 inhibitors led a significantly greater change in the bodyweight (WMD −2.01 kg, 95% CI: −2.18 to −1.83 kg, *P* \< 0.001, in random‐effects). Compared with a placebo, SGLT2 inhibitors as monotherapy also led a significantly greater decrease in bodyweight (WMD −1.95 kg, 95% CI: −2.13 to −1.77 kg, *P* \< 0.001, in random‐effects). As add‐on therapy, compared with a placebo, SGLT2 inhibitors led a significantly greater decrease in bodyweight (WMD −2.04 kg, 95% CI: −2.26 to −1.82 kg, *P* \< 0.001, in random‐effects). Details are shown in Table [2](#jdi12625-tbl-0002){ref-type="table-wrap"}. Results from the meta‐regression analysis (Figure [S3](#jdi12625-sup-0002){ref-type="supplementary-material"}) suggested that the bodyweight changes in SGLT2 inhibitors treatment was not associated with baseline BMI (β 0.179, 95% CI: −0.804 to 1.162, *P* \> 0.05), or baseline HbA1c (β −1.639, 95% CI: −8.24 to 4.96, *P* \> 0.05), or HbA1c changes from baseline (β 0.001, 95% CI: −5.20 to 5.20, *P* \> 0.05) or baseline bodyweight (β 0.026, 95% CI: −0.253 to 0.305, *P* \> 0.05).

###### 

Comparisons of the weight changes from baseline between sodium‐glucose cotransporter 2 inhibitors treatment and glucagon‐like peptide‐1 analogs treatment

  Variables                          SGLT2 inhibitors treatment   GLP‐1 analogs treatment                                                                                                                                                                            
  ---------------------------------- ---------------------------- ------------------------- ---------------------------------------------- -------------- --------- ----- ---- ------------- ---------------------------------------------- -------------- --------- ------
  Weight change from baseline (kg)                                                                                                                                                                                                                                   
  Monotherapy                        17                           1,750/1,649               −1.95[a](#jdi12625-note-0003){ref-type="fn"}   −2.13, −1.77   \<0.001   96%   9    671/700       −1.22[a](#jdi12625-note-0003){ref-type="fn"}   −1.61, −0.83   \<0.001   98%
  Add‐on therapy                     34                           6,972/6,520               −2.04[a](#jdi12625-note-0003){ref-type="fn"}   −2.26, −1.82   \<0.001   99%   28   4,838/3,808   −1.70[a](#jdi12625-note-0003){ref-type="fn"}   −2.02, −1.39   \<0.001   100%
  Total                              51                           8,710/8,151               −2.01[a](#jdi12625-note-0003){ref-type="fn"}   −2.18, −1.83   \<0.001   99%   37   5,509/4,508   −1.59[a](#jdi12625-note-0003){ref-type="fn"}   −1.86, −1.32   \<0.001   100%
  HbA1c change from baseline (%)                                                                                                                                                                                                                                     
  Monotherapy                        17                           1,750/1,649               −0.78[a](#jdi12625-note-0003){ref-type="fn"}   −0.87, −0.70   \<0.001   98%   15   1,674/1,030   −1.05[a](#jdi12625-note-0003){ref-type="fn"}   −1.25, −0.84   \<0.001   98%
  Add‐on therapy                     34                           6,972/6,520               −0.58[a](#jdi12625-note-0003){ref-type="fn"}   −0.62, −0.53   \<0.001   99%   31   5,735/3,974   −0.75[a](#jdi12625-note-0003){ref-type="fn"}   −0.85, −0.66   \<0.001   100%
  Total                              51                           8,710/8,151               −0.64[a](#jdi12625-note-0003){ref-type="fn"}   −0.68, −0.60   \<0.001   99%   46   7,409/5,004   −0.84[a](#jdi12625-note-0003){ref-type="fn"}   −0.94, −0.74   \<0.001   100%

*P* \< 0.001. CI, confidence interval; GLP‐1, glucagon‐like peptide‐1; HBA1c, glycated hemoglobin; SGLT2, sodium‐glucose cotransporter 2; WMD, weighted mean difference.

John Wiley & Sons, Ltd

Subgroup analysis was based on the efficacy of bodyweight in different kinds of SGLT2 inhibitors treatment. The results showed that dapagliflozin treatment led to a significantly greater decrease in the bodyweight when compared with a placebo (WMD −1.92 kg, 95% CI: −2.11 to −1.72 kg, *P* \< 0.001, in random‐effects); canagliflozin treatment was associated with a significantly greater bodyweight reduction when compared with a placebo (WMD −2.30 kg, 95% CI: −2.73 to −1.88 kg, *P* \< 0.001, in random‐effects); empagliflozin treatment resulted in a significantly greater weight reduction when compared with a placebo (WMD −1.95 kg, 95% CI: −2.07 to −1.83 kg, *P* \< 0.001, in random‐effects); and ipragliflozin treatment also led to a significantly greater reduction in bodyweight when compared with a placebo (WMD −1.72 kg, 95% CI: −1.90 to −1.54 kg, *P* \< 0.001, in random‐effects). Details are shown in Table [3](#jdi12625-tbl-0003){ref-type="table-wrap"}.

###### 

Comparisons of the weight changes and glycated hemoglobin changes from baseline in different sodium‐glucose cotransporter 2 inhibitors treatment

                                     No. studies   No. participants (SGLT2i vs placebo)   WMD from baseline                              95% CI         *P*‐value
  ---------------------------------- ------------- -------------------------------------- ---------------------------------------------- -------------- -----------
  Weight change from baseline (kg)                                                                                                                      
  Dapagliflozin                      20            2,954/2,971                            −1.92[a](#jdi12625-note-0004){ref-type="fn"}   −2.11, −1.72   \<0.001
  Canagliflozin                      11            2,781/2,551                            −2.30[a](#jdi12625-note-0004){ref-type="fn"}   −2.73, −1.88   \<0.001
  Empagliflozin                      13            2,495/2,288                            −1.95[a](#jdi12625-note-0004){ref-type="fn"}   −2.07, −1.83   \<0.001
  Ipragliflozin                      4             370/237                                −1.72[a](#jdi12625-note-0004){ref-type="fn"}   −1.90, −1.54   \<0.001
  Tofogliflozin                      2             122/122                                −2.15[a](#jdi12625-note-0004){ref-type="fn"}   −2.82, −1.48   \<0.001
  Total                              51            8,710/8,151                            −2.01[a](#jdi12625-note-0004){ref-type="fn"}   −2.18, −1.83   \<0.001
  HbA1c change from baseline (%)                                                                                                                        
  Dapagliflozin                      20            2,954/2,971                            −0.58[a](#jdi12625-note-0004){ref-type="fn"}   −0.65, −0.52   \<0.001
  Canagliflozin                      11            2,781/2,551                            −0.75[a](#jdi12625-note-0004){ref-type="fn"}   −0.82, −0.68   \<0.001
  Empagliflozin                      13            2,495/2,288                            −0.64[a](#jdi12625-note-0004){ref-type="fn"}   −0.71, −0.56   \<0.001
  Ipragliflozin                      4             370/237                                −0.68[a](#jdi12625-note-0004){ref-type="fn"}   −1.02, −0.35   \<0.001
  Tofogliflozin                      2             122/122                                −0.73[a](#jdi12625-note-0004){ref-type="fn"}   −0.77, −0.69   \<0.001
  Total                              51            8,710/8,151                            −0.64[a](#jdi12625-note-0004){ref-type="fn"}   −0.68, −0.60   \<0.001

*P* \< 0.001. CI, confidence interval; HBA1c, glycated hemoglobin; SGLT2, sodium‐glucose cotransporter 2; WMD, weighted mean difference.

John Wiley & Sons, Ltd

Weight changes in GLP‐1 analogs treatment {#jdi12625-sec-0014}
-----------------------------------------

When GLP‐1 analogs treatment was compared with placebo treatment, the results suggested that GLP‐1 analogs led to a significantly greater decrease in bodyweight (WMD −1.59 kg, 95% CI: −1.86 to −1.32 kg, *P* \< 0.001, in random‐effects). Compared with the placebo, GLP‐1 analogs as monotherapy led to a comparable decrease in bodyweight (WMD −1.22 kg, 95% CI: −1.61 to −0.83, *P* \< 0.001, in random‐effects). As add‐on therapy, compared with the placebo, GLP‐1 analogs led to a significantly greater decrease in bodyweight (WMD −1.70 kg, 95% CI: −2.02 to −1.39 kg, *P* \< 0.001, in random‐effects). Results from meta‐regression analysis suggested that the bodyweight changes in GLP‐1 analogs treatment was not associated with baseline BMI (β −0.058, 95% CI: −0.204 to 0.088, *P* \> 0.05), or baseline HbA1c (β −0.524, 95% CI: −3.066 to 2.019, *P* \> 0.05), or the HbA1c changes from baseline (β −1.716, 95% CI: −4.216 to 0.784, *P* \> 0.05), but the bodyweight changes in GLP‐1 analogs treatment was significantly associated with baseline bodyweight (β 0.092, 95% CI: −0.154 to −0.03, *P* = 0.005). Details are shown in Figure [S4](#jdi12625-sup-0002){ref-type="supplementary-material"}.

Subgroup analysis was based on the efficacy of bodyweight in different kinds of GLP‐1 analogs treatment. The results suggested that exenatide treatment led to a significantly greater decrease in bodyweight when compared with the placebo (WMD −1.69 kg, 95% CI: −2.09 to −1.29 kg, *P* \< 0.001, in random‐effects); liraglutide treatment resulted in a significantly greater reduction in bodyweight when compared with the placebo (WMD −2.51 kg, 95% CI: −3.33 to −1.69 kg, *P* \< 0.001, in random‐effects); lixisenatide treatment was associated with a significantly greater weight reduction when compared with the placebo (WMD −0.90 kg, 95% CI: −1.24 to −0.56 kg, *P* \< 0.001, in random‐effects); and taspoglutide treatment also led to a significantly greater weight reduction when compared with the placebo (WMD 1.40 kg, 95% CI: −1.45 to −1.35 kg, *P* \< 0.001, in random‐effects). For treatment with GLP‐1 analogs daily dosage and weekly dosage one, the bodyweight decrease from baseline was also significant when compared with the placebo. Details are shown in Table [4](#jdi12625-tbl-0004){ref-type="table-wrap"}.

###### 

Comparisons of the weight changes and glycated hemoglobin changes from baseline in different glucagon‐like peptide‐1analogs treatment

                                     No. studies   No. participants (GLP‐1 vs placebo)   WMD from baseline                              95% CI         *P*‐value
  ---------------------------------- ------------- ------------------------------------- ---------------------------------------------- -------------- -----------
  Weight change from baseline (kg)                                                                                                                     
  Exenatide                          10            983/990                               −1.69[a](#jdi12625-note-0005){ref-type="fn"}   −2.09, −1.29   \<0.001
  Liraglutide                        7             1,158/825                             −2.51[a](#jdi12625-note-0005){ref-type="fn"}   −3.33, −1.69   \<0.001
  Lixisenatide                       12            2,350/1,915                           −0.90[a](#jdi12625-note-0005){ref-type="fn"}   −1.24, −0.56   \<0.001
  Albiglutide                        3             450/316                               −0.21                                          −0.50, 0.08    0.16
  Taspoglutide                       3             470/364                               −1.40[a](#jdi12625-note-0005){ref-type="fn"}   −1.45, −1.35   \<0.001
  Dulaglutide                        2             99/98                                 −1.07                                          −3.74, 1.61    0.43
  Daily injections                   28            4,475/3,715                           −1.32[a](#jdi12625-note-0005){ref-type="fn"}   −1.58, −1.06   \<0.001
  Weekly injections                  9             1,034/793                             −1.67[a](#jdi12625-note-0005){ref-type="fn"}   −2.17, −1.17   \<0.001
  Total                              37            5,509/4,508                           −1.59[a](#jdi12625-note-0005){ref-type="fn"}   −1.86, −1.32   \<0.001
  HbA1c change from baseline (%)                                                                                                                       
  Exenatide                          12            1,740/1,107                           −0.82[a](#jdi12625-note-0005){ref-type="fn"}   −0.96, −0.68   \<0.001
  Liraglutide                        12            1,963/1,059                           −1.18[a](#jdi12625-note-0005){ref-type="fn"}   −1.39, −0.97   \<0.001
  Lixisenatide                       12            2,350/1,915                           −0.47[a](#jdi12625-note-0005){ref-type="fn"}   −0.57, −0.38   \<0.001
  Albiglutide                        3             450/316                               −0.78[a](#jdi12625-note-0005){ref-type="fn"}   −0.94, −0.62   \<0.001
  Taspoglutide                       3             470/364                               −0.99[a](#jdi12625-note-0005){ref-type="fn"}   −1.30, −0.69   \<0.001
  Dulaglutide                        5             436/243                               −1.15[a](#jdi12625-note-0005){ref-type="fn"}   −1.45, −0.86   \<0.001
  Daily injections                   34            6,022/4,067                           −0.75[a](#jdi12625-note-0005){ref-type="fn"}   −0.86, −0.65   \<0.001
  Weekly injections                  12            1,387/937                             −1.07[a](#jdi12625-note-0005){ref-type="fn"}   −1.25, −0.89   \<0.001
  Total                              46            7,409/5,004                           −0.84[a](#jdi12625-note-0005){ref-type="fn"}   −0.94, −0.74   \<0.001

*P* \< 0.001. CI, confidence interval; GLP‐1, glucagon‐like peptide‐1; HBA1c, glycated hemoglobin; WMD, weighted mean difference.

John Wiley & Sons, Ltd

Comparisons of weight changes from baseline between SGLT2 inhibitors and GLP‐1 analogs treatment {#jdi12625-sec-0015}
------------------------------------------------------------------------------------------------

In total, comparisons of weight changes from baseline corrected by placebo between SGLT2 inhibitors and GLP‐1 analogs treatment showed that the difference was not significant (*P* \> 0.05). For HbA1c changes from baseline corrected by placebo between SGLT2 inhibitors and GLP‐1 analogs treatment, neither showed a significant difference (*P* \> 0.05).

Discussion {#jdi12625-sec-0016}
==========

It is well known that treatment with GLP‐1 analogs both in monotherapy and add‐on therapy can lead to weight decrease from baseline in type 2 diabetes patients, which were reported by some randomized clinical trials[8](#jdi12625-bib-0008){ref-type="ref"}, [9](#jdi12625-bib-0009){ref-type="ref"}, [10](#jdi12625-bib-0010){ref-type="ref"}, [16](#jdi12625-bib-0016){ref-type="ref"}, [17](#jdi12625-bib-0017){ref-type="ref"} and meta‐analyses[18](#jdi12625-bib-0018){ref-type="ref"}, [19](#jdi12625-bib-0019){ref-type="ref"}, [20](#jdi12625-bib-0020){ref-type="ref"}. Group analysis and subgroup analysis of the current meta‐analysis also showed the comparable effect of weight loss in GLP‐1 analogs treatment. Furthermore, from the results of the present meta‐analysis, SGLT2 inhibitors also resulted in significantly greater weight loss. Comparisons between the two kinds of treatment of the placebo‐corrected weight changes showed no significant difference. So far, few studies have made comparisons between these two kinds of hypoglycemic treatment in terms of weight change; therefore, the present meta‐analysis comprehensively evaluated the weight changes between these two groups of antidiabetes treatment.

Subgroup analysis showed that dapagliflozin, canagliflozin, empagliflozin and ipragliflozin all led to weight reductions, which is also consistent with previous results from randomized controlled trials in monotherapy and add‐on therapy in type 2 diabetes patients[14](#jdi12625-bib-0014){ref-type="ref"}, [21](#jdi12625-bib-0021){ref-type="ref"}, [22](#jdi12625-bib-0022){ref-type="ref"}, [23](#jdi12625-bib-0023){ref-type="ref"}. Recently published longer‐term data of empagliflozin[24](#jdi12625-bib-0024){ref-type="ref"} also showed that the placebo‐corrected reduction in bodyweight was 2.5 kg in average. Weight loss in SGLT2 inhibitors treatment might be explained as being due to caloric loss through glucose excretion in the urine, which could result in a shift toward negative net energy balance. Another explanation by Bolinder *et al*.[14](#jdi12625-bib-0014){ref-type="ref"} suggested that with dapagliflozin treatment, 'the bodyweight loss could be explained by reduced total body fat mass, visceral adipose tissue and subcutaneous adipose tissue volume.' However, reasons for the weight loss in GLP‐1 analogs treatment were suggested as mediating through effects on appetite sensations and subsequent reduction of energy intake, rather than increasing energy expenditure[25](#jdi12625-bib-0025){ref-type="ref"}, which were different from those for SGLT2 inhibitors treatment.

So far, no head‐to‐head clinical comparative trial has reported on the weight changes between GLP‐1 analogs treatment and SGLT2 inhibitors treatment. However, these two antidiabetes agents have different mechanisms in glycemic control and weight control; one of which for SGLT2 inhibitors is through inhibition of renal glucose reabsorption by SGLT2, providing an insulin‐independent mechanism for lowering blood glucose[26](#jdi12625-bib-0026){ref-type="ref"}, another of which for GLP‐1 analogs is an analog of an incretin hormone that enhances glucose‐dependent insulin secretion, inhibiting glucagon secretion and slowing gastric emptying[27](#jdi12625-bib-0027){ref-type="ref"}, [28](#jdi12625-bib-0028){ref-type="ref"}, [29](#jdi12625-bib-0029){ref-type="ref"}. Therefore, the results of the present meta‐analysis should be cautiously explained. However, we might conclude that both of the two kinds of antidiabetes treatment could lead to significant weight reduction, which is an important issue for type 2 diabetes patients.

It was suggested that obesity was associated with diabetes and insulin resistance[30](#jdi12625-bib-0030){ref-type="ref"}, [31](#jdi12625-bib-0031){ref-type="ref"}. Weight loss is an additional treatment goal for most patients with type 2 diabetes, and a degree of weight loss was associated with improvements in glycemic control and cardiovascular risk factors[5](#jdi12625-bib-0005){ref-type="ref"}, [6](#jdi12625-bib-0006){ref-type="ref"}. Currently, treatments for type 2 diabetes associated with weight neutral are dipeptidyl peptidase‐4 inhibitors and alpha glucose inhibitor; treatments associated with weight increase are sulfonylureas, insulin and thiazolidinediones; and treatment associated with small weight reduction us metformin[1](#jdi12625-bib-0001){ref-type="ref"}, [3](#jdi12625-bib-0003){ref-type="ref"}. The new mode therapies for type 2 diabetes, such as GLP‐1 analogs and SGLT2 inhibitors, has led to significant weight changes in type 2 diabetes treatments, as concluded from the present meta‐analysis. However, these two kinds of treatments also have some limitations. GLP‐1 analogs must be injected, and were reported to be associated with gastrointestinal side‐effects[18](#jdi12625-bib-0018){ref-type="ref"}, [19](#jdi12625-bib-0019){ref-type="ref"}, whereas SGLT2 inhibitors were reported to be associated with ketoacidosis, osteoporosis and imbalance of electrolytes[32](#jdi12625-bib-0032){ref-type="ref"}, [33](#jdi12625-bib-0033){ref-type="ref"}, [34](#jdi12625-bib-0034){ref-type="ref"}, [35](#jdi12625-bib-0035){ref-type="ref"}.

The present meta‐analysis compared the placebo‐corrected weight changes between GLP‐1 analogs treatment and SGLT2 inhibitors treatment in a large number of randomized controlled trials in type 2 diabetes patients. However, this meta‐analysis still had some limitations. First, although there were differences among separate studies in the inclusion criteria, baseline variables and so on, data should be combined together to evaluate the effects on bodyweight. Second, data on weight changes from baseline in each treatment group could only be collected from 53 studies, and 18 others that lacked this information were excluded from this analysis, which might indicate the presence of selection bias. Third, as the positive results might be published more easily than the negative results, there could be some publication bias in the meta‐analysis. We have carried out the visual inspection of the funnel plot to minimize this limitation. Additionally, the number of trials included in SGLT2 inhibitors treatment and GLP‐1 analogs treatment might not be comparable. Therefore, we should interpret the results from the present meta‐analysis with caution.

The results from the present meta‐analysis suggested that SGLT2 inhibitors, as well as GLP‐1 analogs, led to comparable placebo‐corrected bodyweight decrease in type 2 diabetes patients.
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**Table S1** \| Characteristics of randomized controlled trials in type 2 diabetes included in the meta‐analysis.
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Click here for additional data file.
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**Figure S1** \| Summary of risk of bias of included studies in glucagon‐like peptide‐1 analogs treatment.

**Figure S2** \| Summary of risk of bias of included studies in sodium‐glucose cotransporter 2 inhibitors treatment.

**Figure S3** \| Regression analysis of the associations between the weight changes from baseline and baseline body mass index (BMI), baseline glycated hemoglobin (HbA1c), HbA1c changes from baseline, and baseline weight in sodium‐glucose cotransporter 2 (SGLT2) inhibitors treatment. The size of the circles in this figure did represent the size of each study, which was represented as *N*.

**Figure S4** \| Regression analysis of the associations between the weight changes from baseline and baseline body mass index (BMI), baseline glycated hemoglobin (HbA1c), HbA1c changes from baseline, and baseline weight in glucagon‐like peptide‐1 (GLP‐1) analogs treatment. The size of the circles in this figure did represent the size of each study, which was represented as *N*.

**Figure S5** \| Funnel plot of studies included with glucagon‐like peptide‐1 (GLP‐1) analogs treatment.

**Figure S6** \| Funnel plot of studies included with sodium‐glucose cotransporter 2 inhibitors treatment.
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